The results of a multicentre double-blind trial are reported in which α-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebut anol (terfenadine, RMI 9918, Triludan®, Teldane®, resp.) and dexchlorpheniramine were compared with placebo in the treatment of allergic rhinitis. Terfenadine and dexchlorpheniramine were found to be equally effective; but terfenadine produced less drowsiness and was effective in a twice daily dosage.
Melillo, G., D'Amato, G., Zanussi, C., Ortolani, C., Pastorello, E., Loy, M., et al. (1982). A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis. ARZNEIMITTEL-FORSCHUNG, 32(9 A), 1202-1203.
A multicentre controlled trial of terfenadine, dexchlorpheniramine, and placebo in allergic rhinitis.
P. Sestini;P. Rottoli
1982-01-01
Abstract
The results of a multicentre double-blind trial are reported in which α-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebut anol (terfenadine, RMI 9918, Triludan®, Teldane®, resp.) and dexchlorpheniramine were compared with placebo in the treatment of allergic rhinitis. Terfenadine and dexchlorpheniramine were found to be equally effective; but terfenadine produced less drowsiness and was effective in a twice daily dosage.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/31236
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo